As a biotechnology firm ready for Phase 2, Glycyx is pioneering a novel therapeutic solution that reverses the negative effects and is designed to further enhance the lives of cancer patients by ensuring that essential pain management does not compromise the effectiveness of anti-PD1/PD-L1 cancer treatments. Our mission is to significantly improve survival rates and quality of life for cancer patients worldwide.